Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 4/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060225 | 1.00 | NOS2 (0.52) | NOS2NOS3NOS1HPGDLMNA | |
| SCHEMBL6059739 | 1.00 | NOS2 (0.52) | NOS2NOS3NOS1HPGDLMNA | |
| SCHEMBL6060227 | 1.00 | NOS2 (0.52) | NOS2NOS3NOS1HPGDLMNA | |
| SCHEMBL7420415 | 0.83 | NOS2 (0.49) | NOS2NOS3NOS1LMNAMIF | |
| SCHEMBL7420416 | 0.83 | NOS2 (0.49) | NOS2NOS3NOS1LMNAMIF | |
| SCHEMBL6995211 | 0.83 | NPFFR2 (0.45) | NOS2NOS3NOS1HPGDNPFFR2 | |
| SCHEMBL6992245 | 0.83 | NOS2 (0.49) | NOS2NOS3NOS1LMNAMIF | |
| SCHEMBL6995209 | 0.83 | NPFFR2 (0.45) | NOS2NOS3NOS1HPGDNPFFR2 | |
| SCHEMBL6992247 | 0.83 | NOS2 (0.49) | NOS2NOS3NOS1LMNAMIF | |
| SCHEMBL28364140 | 0.81 | CHRM5 (0.47) | HPGDLMNAKMT2ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6951889-B2 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1429777-A4 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1528921-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | Pharmacia Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1317421-B1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORP (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097163-A2 | USING A SELECTIVE INOS INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1317421-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003026638-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026668-A1 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | disclosed |
| WO-2002022562-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | NOS2 11/4885NOS3 22/4885NOS1 20/4885 |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | NOS2 1/4885NOS3 3/4885NOS1 2/4885 |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | NOS2 8/4885NOS3 14/4885NOS1 10/4885 |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | NOS2 8/4885NOS3 14/4885NOS1 10/4885 |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS3 3/4885NOS1 2/4885 |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | NOS2, NOS1, NLN | NOS2 1/4885NOS3 4/4885NOS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.